The government is quietly backing the development of three new Ebola vaccines. Whitehall sources confirm that British scientists are at the forefront of the push. The message: we cannot afford another pandemic blindside. The projects, funded through the UK Vaccine Network, aim to move beyond the single-shot Ervebo. They target multiple strains, including the deadly Sudan variety. One insider calls it 'a hedge against virological roulette.'
The move is politically savvy. Labour has been sharpening its knives over pandemic preparedness. This gives the government cover. A senior minister told me: 'We can't just talk about lessons learned. We need to show we've acted.' The timing matters. With winter approaching and new variants lurking, the optics are favourable.
But the real game is about influence. The UK wants to shape the global vaccine architecture. These jabs could be stockpiled for outbreak hotspots. The Foreign Office is involved. It sees this as soft power with a hard edge. The Americans are watching. The EU is watching. So are the Chinese.
There is a domestic angle too. The programme bolsters Britain's reputation as a science superpower. It keeps the talent here. It attracts investment. And it distracts from other health service woes. The opposition is wary. One shadow health spokesperson muttered: 'Good news, but let's see if they fund the NHS properly.'
The backbenches are restless. Some Tory MPs want more clarity on cost. Others fear it's a distraction from the economy. The whips are working the phones. They'll manage the usual suspects. For now, the mood is cautiously supportive.
More details are expected next week. The prime minister will flag it at the UN General Assembly. Expect grand talk of 'global leadership'. Behind the scenes, the scramble for contracts is already underway. The usual players are circling.
This is a classic Westminster move. Pre-empt the crisis. Control the narrative. Build the coalition. But viruses don't care about political strategy. The real test will be speed and access. If the jabs work, the credit will flow. If they flop, the recriminations will be brutal. For now, the government is betting the house on British science.
